We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

BECKMAN COULTER, INC.

Beckman Coulter develops, manufactures and markets laboratory systems, reagents, centrifugation, lab automation, elec... read more Featured Products: More products

Download Mobile App





Beckman Coulter Unveils New DxI 9000 Access Immunoassay Analyzer

By LabMedica International staff writers
Posted on 24 May 2023
Print article
Image: The DxI 9000 Access immunoassay analyzer enables elite laboratory performance with no daily maintenance (Photo courtesy of Beckman Coulter)
Image: The DxI 9000 Access immunoassay analyzer enables elite laboratory performance with no daily maintenance (Photo courtesy of Beckman Coulter)

The 25th WorldLab-EuroMedLab Congress will see the global unveiling of a brand-new high throughput immunoassay analyzer by Beckman Coulter, Inc. (Brea, CA, USA).

Visitors to the Beckman Coulter at EuroMedLab 2023 will get a first look at the new DxI 9000 Access immunoassay analyzer that is designed for superior laboratory performance and demands no daily maintenance. The DxI 9000 is the most efficient immunoassay analyzer in terms of footprint, boasting the ability to process up to 215 tests per hour per square meter (tests/hr/m2). The DxI 9000 Analyzer’s cutting-edge features cater to the current demands for speed, reliability, consistency, quality, and menu expansion. Its unique ZeroDaily Maintenance feature further enhances the device's uptime performance, as confirmed by beta users who report that it redefines their workday by eliminating daily maintenance tasks and reducing yearly maintenance routines by up to a staggering 96%.

The DxI 9000 Analyzer is equipped with the state-of-the-art PrecisionVision Technology, capable of scrutinizing, identifying, and preventing inaccurate reporting in real-time. Beckman Coulter's newly-introduced remote service and diagnostic solution, DxS IntelliServe, connects with DxI 9000 Analyzers, keeping track of data and error patterns, and facilitating proactive system servicing when necessary. Additionally, Beckman Coulter is presenting educational workshops on three subject areas – ‘Intelligent automation for laboratories of all sizes’, ‘Creating a culture of innovation in your laboratory’ and ‘Early recognition of severe infection and risk of sepsis’.

Related Links:
Beckman Coulter, Inc.

Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
New
Gold Member
LEISHMANIA Test
LEISHMANIA ELISA
New
Parasite Suspension for QC
Cryptosporidium Species Parasite Suspension
New
Malaria Rapid Test
ASSURE Malaria P.f/P.v Rapid Test

Print article

Channels

Molecular Diagnostics

view channel
Image: Umbilical cord blood biomarkers may improve preterm infant care (Photo courtesy of Shutterstock)

Umbilical Cord Blood Test Could Identify Preterm Infants at Risk for Medical Complications

Advancements in medical technology and neonatology have significantly improved the care of prematurely born infants. However, these infants still face heightened risks for medical complications, such as... Read more

Immunology

view channel

3D Bioprinted Gastric Cancer Model Uses Patient-Derived Tissue Fragments to Predict Drug Response

Tumor heterogeneity presents a major obstacle in the development and treatment of cancer therapies, as patients' responses to the same drug can differ, and the timing of treatment significantly influences prognosis. Consequently, technologies that predict the effectiveness of anticancer treatments are essential in minimizing... Read more

Microbiology

view channel
Image: The Cytovale System isolates, images, and analyzes cells (Photo courtesy of Cytovale)

Rapid Sepsis Diagnostic Test Demonstrates Improved Patient Care and Cost Savings in Hospital Application

Sepsis is the leading cause of death and the most expensive condition treated in U.S. hospitals. The risk of death from sepsis increases by up to 8% for each hour that treatment is delayed, making early... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.